NEXGEL, Inc. (NXGL)
USD 2.62
(-0.38%)
USD 2.62
(-0.38%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 98 Thousand USD | -90.02% |
| 2022 | 982 Thousand USD | 110.81% |
| 2021 | -9.08 Million USD | -829.8% |
| 2020 | 1.24 Million USD | 89.79% |
| 2019 | 656 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.92 Million USD | 194.95% |
| 2024 Q1 | 653 Thousand USD | 566.33% |
| 2023 Q4 | 98 Thousand USD | 111.0% |
| 2023 FY | 98 Thousand USD | -90.02% |
| 2023 Q3 | -891 Thousand USD | 34.49% |
| 2023 Q1 | 1.59 Million USD | 61.91% |
| 2023 Q2 | -1.36 Million USD | -185.53% |
| 2022 Q2 | -1.02 Million USD | 86.24% |
| 2022 Q3 | 695 Thousand USD | 167.94% |
| 2022 Q1 | -7.43 Million USD | 18.19% |
| 2022 FY | 982 Thousand USD | 110.81% |
| 2022 Q4 | 982 Thousand USD | 41.29% |
| 2021 Q4 | -9.08 Million USD | -495.73% |
| 2021 FY | -9.08 Million USD | -829.8% |
| 2021 Q3 | 2.29 Million USD | -10.03% |
| 2021 Q2 | 2.55 Million USD | 655.03% |
| 2021 Q1 | 338 Thousand USD | -72.85% |
| 2020 Q2 | 1.03 Million USD | 54.63% |
| 2020 Q1 | 670 Thousand USD | 2.13% |
| 2020 FY | 1.24 Million USD | 89.79% |
| 2020 Q4 | 1.24 Million USD | 14.43% |
| 2020 Q3 | 1.08 Million USD | 5.02% |
| 2019 Q4 | 656 Thousand USD | -23.27% |
| 2019 Q3 | 855 Thousand USD | 8.23% |
| 2019 FY | 656 Thousand USD | 0.0% |
| 2019 Q2 | 790 Thousand USD | -21.08% |
| 2019 Q1 | 1 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | 96.203% |
| AngioDynamics, Inc. | -70.14 Million USD | 100.14% |
| AtriCure, Inc. | -9.81 Million USD | 100.998% |
| Avinger, Inc. | 10.12 Million USD | 99.032% |
| Azenta, Inc. | -618.47 Million USD | 100.016% |
| BioLife Solutions, Inc. | 7.25 Million USD | 98.649% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 99.996% |
| Daxor Corporation | 755.65 Thousand USD | 87.031% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | 106.667% |
| Femasys Inc. | -15.01 Million USD | 100.653% |
| GlucoTrack, Inc. | -4.29 Million USD | 102.281% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 99.745% |
| Hologic, Inc. | 374.4 Million USD | 99.974% |
| ICU Medical, Inc. | 1.45 Billion USD | 99.993% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 100.004% |
| KORU Medical Systems, Inc. | -7.03 Million USD | 101.393% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | 101.894% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 102.286% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 102.286% |
| Masimo Corporation | 804 Million USD | 99.988% |
| Microbot Medical Inc. | -2.28 Million USD | 104.287% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | 101.021% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 99.968% |
| Nephros, Inc. | -2.47 Million USD | 103.966% |
| NovoCure Limited | 355.42 Million USD | 99.972% |
| NEXGEL, Inc. | 98 Thousand USD | 0.0% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 99.834% |
| OraSure Technologies, Inc. | -276.9 Million USD | 100.035% |
| Pro-Dex, Inc. | 10.91 Million USD | 99.102% |
| Pulse Biosciences, Inc. | -35.22 Million USD | 100.278% |
| Predictive Oncology Inc. | -5.87 Million USD | 101.669% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | 96.765% |
| QuidelOrtho Corporation | 2.49 Billion USD | 99.996% |
| Repligen Corporation | -39.51 Million USD | 100.248% |
| Sanara MedTech Inc. | 6.64 Million USD | 98.525% |
| STAAR Surgical Company | -147.2 Million USD | 100.067% |
| Sharps Technology, Inc. | -3.01 Million USD | 103.253% |
| Utah Medical Products, Inc. | -92.52 Million USD | 100.106% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 99.995% |
| Jin Medical International Ltd. | -2.81 Million USD | 103.479% |